156 related articles for article (PubMed ID: 23749912)
1. The role of trastuzumab in the management of salivary ductal carcinomas.
Perissinotti AJ; Lee Pierce M; Pace MB; El-Naggar A; Kies MS; Kupferman M
Anticancer Res; 2013 Jun; 33(6):2587-91. PubMed ID: 23749912
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab for the treatment of salivary duct carcinoma.
Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM
Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317
[TBL] [Abstract][Full Text] [Related]
6. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
Nabili V; Tan JW; Bhuta S; Sercarz JA; Head CS
Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907
[TBL] [Abstract][Full Text] [Related]
7. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
Kaidar-Person O; Billan S; Kuten A
Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
[TBL] [Abstract][Full Text] [Related]
9. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
11. Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required?
Lee JS; Kwon OJ; Park JJ; Seo JH
J Oral Maxillofac Surg; 2014 May; 72(5):1023-31. PubMed ID: 24480767
[TBL] [Abstract][Full Text] [Related]
12. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
14. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N
Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650
[TBL] [Abstract][Full Text] [Related]
15. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
[TBL] [Abstract][Full Text] [Related]
16. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
Haddad R; Colevas AD; Krane JF; Cooper D; Glisson B; Amrein PC; Weeks L; Costello R; Posner M
Oral Oncol; 2003 Oct; 39(7):724-7. PubMed ID: 12907212
[TBL] [Abstract][Full Text] [Related]
17. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
Ghazali N; Parker L; Settle K; Lubek JE
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263
[TBL] [Abstract][Full Text] [Related]
18. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
Niikura N; Liu J; Hayashi N; Mittendorf EA; Gong Y; Palla SL; Tokuda Y; Gonzalez-Angulo AM; Hortobagyi GN; Ueno NT
J Clin Oncol; 2012 Feb; 30(6):593-9. PubMed ID: 22124109
[TBL] [Abstract][Full Text] [Related]
19. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
Nardi V; Sadow PM; Juric D; Zhao D; Cosper AK; Bergethon K; Scialabba VL; Batten JM; Borger DR; Iafrate AJ; Heist RS; Lawrence DP; Flaherty KT; Bendell JC; Deschler D; Li Y; Wirth LJ; Dias-Santagata D
Clin Cancer Res; 2013 Jan; 19(2):480-90. PubMed ID: 23186780
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Takahashi H; Tada Y; Saotome T; Akazawa K; Ojiri H; Fushimi C; Masubuchi T; Matsuki T; Tani K; Osamura RY; Hirai H; Yamada S; Kawakita D; Miura K; Kamata SE; Nagao T
J Clin Oncol; 2019 Jan; 37(2):125-134. PubMed ID: 30452336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]